Imricor Medical Systems (ASX:IMR) reported a total revenue of $132,000 for the March quarter, with its consumables revenue of $104,000 up 385% year-over-year, according to a Wednesday Australian bourse filing.
The firm reported net cash inflows from financing activities of $43 million in the March quarter, comprising net proceeds from the completion of the placement. Meanwhile, its net cash outflows from operating activities came in at $4.6 million.
It also established Imricor BV, a wholly-owned subsidiary in the Netherlands, during the quarter. It hired the first capital sales managers in the US in preparation for a US commercial launch.
On April 10, the first-in-man ventricular ablation guided by real-time interventional cardiac magnetic resonance was performed at the Amsterdam University Medical Centre.
Its shares rose 5% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。